박기덕, Park, Ki Duk

Principal Researcher

OFFICE

L2307, +82-958-5132

LAB

L2318, +82-958-5172

EDUCATION

Ph.D. Department of Biotechnology Yonsei University (2004)
M.S. Department of Biotechnology Yonsei University (2001)
B.S. Department of Biotechnology Yonsei University (1999)

RESEARCH CAREER & ACTIVITIES
  • Principal Research Scientist (2016 – present), Senior Research Scientist (2011 – 2015) : Convergence Research Center for Brain Science, Korea Institute of Science and Technology (KIST)
  •  Professor (2016 – present), Associate Professor (2012 – 2015): Division of Bio-Med Science & Technology, KIST School, University of Science and Technology (UST)
  • Postdoctoral Research Associate (2006 – 2011): Division of Medicinal Chemistry and Natural Products, Eshelman School of Pharmacy, University of North Carolina at Chapel Hill.
  • Post-doctor (2004 – 2006)- Army service: Laboratory of Cellular Function Modulator, Korea Research Institute of Bioscience and Biotechnology.
RESEARCH INTERESTS
  • Medicinal Chemistry
    – Novel inhibitors of abberrant GABA synthesis in reactive astrocytes
    – Nrf2 activators for treatment of neurodegenerative diseases (AD, PD)
    – Development of biased agonists against S1P receptors for treatment of multiple sclerosis
    – GPCR target-based drug discovery for neurological disorders (depression, neuropathic pain etc)
  • Neurobiology – Drug Efficacy & Therapeutic Mechanism
    – in vitro efficacy (protein-based & cell-based tests)
    – in vivo efficacy (AD, PD, MS etc)
    – ADME/Tox (Drug-like properties)
  • Chemical Biology
    – Identification of Nrf2 activating mechanism in neurodegenerative diseases (AD, PD)
    – Identification of target site & mode of action using chemicals
    – Study on neuroinflammation pathway & therapeutic strategies in neurological disorders
HIGHLIGHT
  • Discovery of Novel Sphingosine-1-Phosphate-1 Receptor Agonists for the Treatment of Multiple Sclerosis. Park S. J., Yeon S. K., Kim Y., Kim H. J., Kim S., Kim J., Choi J. W., Kim B., Lee E. H., Kim R., Seo S. H., Lee J., Kim J. W., Lee H. Y., Hwang H., Bahn Y. S., Cheong E., Park J. H., Park K. D.  Journal of Medicinal Chemistry. 2022, 65(4), 3539-3562 (Cover)
  • Optimization and evaluation of novel antifungal agents for the treatment of fungal infection. Choi J. W., Lee K. T., Kim S., Lee Y. R., Kim H. J., Seo K. J., Lee M. H., Yeon S. K., Jang B. K., Park S. J., Kim H. J., Park J.-H., Kim D., Lee D. G., Cheong E., Lee J. S., Bahn Y. S., Park K. D. Journal of Medicinal Chemistry. 2021 64, 15912-15935. (Cover)
  • Newly developed reversible MAO-B inhibitor circumvents the shortcomings of irreversible inhibitors in Alzheimer’s disease. Park J.-H., Ju Y. H., Choi J. W., Song H. J., Jang B. K., Woo J. Chun H., Kim H. J., Shin S. J., Yarishkin O., Jo S., Park M., Yeon S. K., Kim S. Kim J., Nam M.-H., Londhe A. M., Kim J., Cho S. J., Cho S. M., Lee C., Hwang S. Y., Kim S. W., Oh S.-J., Cho J., Pae A. N., Lee C. J., Park K. D. Science Advances. 2019, 5(3), eaav0316.
  • Optimization of vinyl sulfone derivatives as potent nuclear factor erythroid 2-related factor 2 (Nrf2) activators for Parkinson’s disease therapy. Choi J. W., Kim S., Park J.-H., Kim H. J., Shin S. J., Kim J. W., Woo S. Y., Lee C., Han S. M., Lee J., Pae A. N., Han G., Park K. D. Journal of Medicinal Chemistry. 2019, 62, 811-830.